Cargando…

Associations between tamoxifen, estrogens, and FSH serum levels during steady state tamoxifen treatment of postmenopausal women with breast cancer

BACKGROUND: The cytochrome P450 (CYP) enzymes 2C19, 2D6, and 3A5 are responsible for converting the selective estrogen receptor modulator (SERM), tamoxifen to its active metabolites 4-hydroxy-tamoxifen (4OHtam) and 4-hydroxy-N-demethyltamoxifen (4OHNDtam, endoxifen). Inter-individual variations of t...

Descripción completa

Detalles Bibliográficos
Autores principales:	Gjerde, Jennifer, Geisler, Jürgen, Lundgren, Steinar, Ekse, Dagfinn, Varhaug, Jan Erik, Mellgren, Gunnar, Steen, Vidar M, Lien, Ernst A
Formato:	Texto
Lenguaje:	English
Publicado:	BioMed Central 2010
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2910688/ https://www.ncbi.nlm.nih.gov/pubmed/20565970 http://dx.doi.org/10.1186/1471-2407-10-313

Ejemplares similares

Serum concentrations of tamoxifen and its metabolites increase with age during steady-state treatment
por: Lien, Ernst A., et al.
Publicado: (2013)

Tissue distribution of 4-hydroxy-N-desmethyltamoxifen and tamoxifen-N-oxide
por: Gjerde, Jennifer, et al.
Publicado: (2012)

Steroid receptor coactivators, HER-2 and HER-3 expression is stimulated by tamoxifen treatment in DMBA-induced breast cancer
por: Moi, Line L Haugan, et al.
Publicado: (2012)

First-in-human pharmacokinetics of tamoxifen and its metabolites in the milk of a lactating mother: a case study
por: Peccatori, Fedro Alessandro, et al.
Publicado: (2020)

The Active Tamoxifen Metabolite Endoxifen (4OHNDtam) Strongly Down-Regulates Cytokeratin 6 (CK6) in MCF-7 Breast Cancer Cells
por: Helland, Thomas, et al.
Publicado: (2015)

Genotype of metabolic enzymes and the benefit of tamoxifen in postmenopausal breast cancer patients
por: Wegman, Pia, et al.
Publicado: (2005)

A Role for Estrogen Receptor Phosphorylation in the Resistance to Tamoxifen
por: de Leeuw, Renée, et al.
Publicado: (2011)

Tamoxifen non-estrogen receptor mediated molecular targets
por: Bogush, Tatiana, et al.
Publicado: (2012)

Serum concentrations of active tamoxifen metabolites predict long-term survival in adjuvantly treated breast cancer patients
por: Helland, Thomas, et al.
Publicado: (2017)

Simultaneous Quantification of Aromatase Inhibitors and Estrogens in Postmenopausal Breast Cancer Patients
por: Bertelsen, Bjørn-Erik, et al.
Publicado: (2021)

Effect of Genetic Variability in 20 Pharmacogenes on Concentrations of Tamoxifen and Its Metabolites
por: Chen, Yuanhuang, et al.
Publicado: (2021)

Endocrine and clinical consequences of combination tamoxifen-aminoglutethimide in postmenopausal breast cancer.
por: Dowsett, M., et al.
Publicado: (1984)

AGR2 Predicts Tamoxifen Resistance in Postmenopausal Breast Cancer Patients
por: Hrstka, Roman, et al.
Publicado: (2013)

Polypoid endometriosis mimicking invasive cancer in an obese, postmenopausal tamoxifen user
por: Jaegle, William T., et al.
Publicado: (2017)

Effects of tamoxifen and exemestane on cognitive function in postmenopausal patients with breast cancer
por: Lee Meeuw Kjoe, Philippe R, et al.
Publicado: (2023)

IARC on tamoxifen.
Publicado: (1996)

Tamoxifen evolution
por: Howell, A., et al.
Publicado: (2023)

Generating a Precision Endoxifen Prediction Algorithm to Advance Personalized Tamoxifen Treatment in Patients with Breast Cancer
por: Helland, Thomas, et al.
Publicado: (2021)

Resuming Sensitivity of Tamoxifen-Resistant Breast Cancer Cells to Tamoxifen by Tetrandrine
por: Wang, Yuntao, et al.
Publicado: (2021)

Quality of life in relation to tamoxifen or exemestane treatment in postmenopausal breast cancer patients: a Tamoxifen Exemestane Adjuvant Multinational (TEAM) Trial side study
por: van Nes, J. G. H., et al.
Publicado: (2012)

Phosphorylated p-70S6K predicts tamoxifen resistance in postmenopausal breast cancer patients randomized between adjuvant tamoxifen versus no systemic treatment
por: Beelen, Karin, et al.
Publicado: (2014)

CYP2C19*2 predicts substantial tamoxifen benefit in postmenopausal breast cancer patients randomized between adjuvant tamoxifen and no systemic treatment
por: Beelen, K., et al.
Publicado: (2013)

Prospective study on gynaecological effects of two antioestrogens tamoxifen and toremifene in postmenopausal women
por: Marttunen, M B, et al.
Publicado: (2001)

Comparative Study on Hysteroscopic and Histologic Examinations of the Endometrium in Postmenopausal Women Taking Tamoxifen
por: Jung, Hyuk, et al.
Publicado: (2018)

A randomized phase II presurgical trial of weekly low-dose tamoxifen versus raloxifene versus placebo in premenopausal women with estrogen receptor-positive breast cancer
por: Serrano, Davide, et al.
Publicado: (2013)

Tamoxifen and the Singing Voice
por: Herxheimer, Andrew
Publicado: (2005)

Chemoprevention: beyond tamoxifen
por: Cuzick, J
Publicado: (2005)

Tamoxifen and Ovarian Function
por: Berliere, Martine, et al.
Publicado: (2013)

Use of antipsychotics with tamoxifen
por: Ghabi, H., et al.
Publicado: (2021)

Quantitative In Situ Measurement of Estrogen Receptor mRNA Predicts Response to Tamoxifen
por: Bordeaux, Jennifer M., et al.
Publicado: (2012)

miRNAs regulated by estrogens, tamoxifen, and endocrine disruptors and their downstream gene targets
por: Klinge, Carolyn M.
Publicado: (2015)

Estrogen receptor alpha in the brain mediates tamoxifen-induced changes in physiology in mice
por: Zhang, Zhi, et al.
Publicado: (2021)

Lnc-DC promotes estrogen independent growth and tamoxifen resistance in breast cancer
por: Peng, Wan-Xin, et al.
Publicado: (2021)

Influence of green tea consumption on endoxifen steady-state concentration in breast cancer patients treated with tamoxifen
por: Braal, C. Louwrens, et al.
Publicado: (2020)

HER4 expression in estrogen receptor-positive breast cancer is associated with decreased sensitivity to tamoxifen treatment and reduced overall survival of postmenopausal women
por: Wege, Anja Kathrin, et al.
Publicado: (2018)

Inhibition of STAT3 enhances sensitivity to tamoxifen in tamoxifen-resistant breast cancer cells
por: Moon, Seo Yun, et al.
Publicado: (2021)

1,25-Dihydroxyvitamin D and the Vitamin D Receptor Gene Polymorphism Apa1 Influence Bone Mineral Density in Primary Hyperparathyroidism
por: Christensen, Monika H. E., et al.
Publicado: (2013)

Tamoxifen Regulates Cell Fate Through Mitochondrial Estrogen Receptor Beta in Breast Cancer
por: Razandi, Mahnaz, et al.
Publicado: (2012)

Phosphorylation of estrogen receptor α at serine 118 is correlated with breast cancer resistance to tamoxifen
por: CHEN, MING, et al.
Publicado: (2013)

The Effect of Selective Estrogen Receptor Modulators (SERMs) on the Tamoxifen Resistant Breast Cancer Cells
por: Chang, Bo Yoon, et al.
Publicado: (2011)

Cannot write session to /tmp/vufind_sessions/sess_9d9qvscsk1dcgfu8599jtbthq9